[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543034":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":46,"centralContacts":50,"locations":59,"responsibleParty":73,"collaborators":76,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":35,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":35,"enrollmentInfo":105,"targetDuration":35,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":61,"whyStopped":35,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Ipsilateral High-Frequency","EXPERIMENTAL","Patients with motor priority confirmed by TUG and TUG-Cog tests.\n\nHigh-frequency (HF) rTMS over more affected primary motor cortex (M1) of lower extremity will be applied.",[13],"Device: High-Frequency, ipsilateral M1",{"label":15,"type":16,"description":17,"interventionNames":18},"Bilateral High-Frequency1","ACTIVE_COMPARATOR","Patients with motor priority confirmed by TUG and TUG-Cog tests.\n\nHigh-frequency (HF) rTMS over bilateral M1 of lower extremities will be applied.",[19],"Device: High-Frequency, bilateral M1",{"label":21,"type":10,"description":22,"interventionNames":23},"DLPFC High-Frequency","Patients with cognitive priority confirmed by TUG and TUG-Cog tests.\n\nHigh-frequency (HF) rTMS over Lt. dorsolateral prefrontal cortex (DLPFC) will be applied.",[24],"Device: High-Frequency, Lt. DLPFC",{"label":26,"type":16,"description":27,"interventionNames":28},"Bilateral High-Frequency2","Patients with cognitive priority confirmed by TUG and TUG-Cog tests.\n\nHigh-frequency (HF) rTMS over bilateral M1 of lower extremities will be applied.",[19],[30,36,40,44],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DEVICE","High-Frequency, ipsilateral M1","rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.\n\nrTMS target: ipsilateral primary motor cortex of lower extremity.\n\nTotal rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.\n\nAdditional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.",[9],null,{"type":31,"name":37,"description":38,"armGroupLabels":39,"otherNames":35},"High-Frequency, bilateral M1","rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.\n\nrTMS target: bilateral primary motor cortex of lower extremity.\n\nTotal rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.\n\nAdditional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.",[15],{"type":31,"name":41,"description":42,"armGroupLabels":43,"otherNames":35},"High-Frequency, Lt. DLPFC","rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.\n\nrTMS target: Lt. DLPFC\n\nTotal rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.\n\nAdditional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.",[21],{"type":31,"name":37,"description":38,"armGroupLabels":45,"otherNames":35},[26],[47],{"name":48,"affiliation":5,"role":49},"Won Hyuk Chang, PhD","PRINCIPAL_INVESTIGATOR",[51,55],{"name":48,"role":52,"phone":53,"phoneExt":35,"email":54},"CONTACT","+82-2-3410-6068","wh.chang@samsung.com",{"name":56,"role":52,"phone":57,"phoneExt":35,"email":58},"Ho Seok Lee, PhD","+82-2-3410-2810","hoseok89.lee@samsung.com",[60],{"facility":5,"status":61,"city":62,"state":35,"zip":63,"country":64,"countryCode":35,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"RECRUITING","Seoul","06351","South Korea",{"type":66,"coordinates":67},"Point",[68,69],126.9784,37.566,{"lat":69,"lon":68},[72],{"name":48,"role":52,"phone":53,"phoneExt":35,"email":54},{"type":49,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"Won Hyuk Chang","Professor",[77,79,82,84,86,88,90,93],{"name":78,"class":6},"National Research Foundation of Korea",{"name":80,"class":81},"Ministry of Food and Drug Safety, Korea","OTHER_GOV",{"name":83,"class":6},"Seoul National University Hospital",{"name":85,"class":6},"Bucheon St. Mary's Hospital",{"name":87,"class":6},"Saint Vincent's Hospital, Korea",{"name":89,"class":6},"Severance Hospital",{"name":91,"class":92},"Kumoh National Institute of Technology","UNKNOWN",{"name":94,"class":95},"NEUROPHET","INDUSTRY","100543034","personalized-rtms-protocol-based-on-functional-reserve-to-enhance-ambulatory-function-in-pd-patients-100543034",false,"NCT06350617","Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients","Safety and Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Ambulatory Function in Patients With Parkinson Disease","Inclusion Criteria:\n\n1. patients with Parkinson's disease, diagnosed by the United Kingdom (UK) Parkinson's Disease Society Brain Bank Diagnostic Criteria,\n2. Modified Hoehn and Yahr (H\\&Y) scale, stage 2\\~4,\n3. patients who can walk on flat surfaces without the need for a gait aid,\n4. aged ≥50 years old,\n5. patients willing to sign the informed consent.\n\nExclusion Criteria:\n\n1. those with contraindications to rTMS, such as epilepsy, implanted metal objects in the head, or a history of craniotomy,\n2. those with cognitive impairment, confirmed through the Montreal Cognitive Assessment (MoCA) test as follows: \\\u003C 7 points: Illiterate \\\u003C 13 points: Education duration 0.5-3 years \\\u003C 16 points: Education duration 4-6 years \\\u003C 19 points: Education duration 7-9 years \\\u003C 20 points: Education duration 10 years or more\n3. those with coexisting neurological conditions, such as spinal cord injury or Stroke,\n4. those with major psychiatric disorders, such as major depression, schizophrenia, or dementia,\n5. those with severe on-off phenomena or severe dyskinesia, deemed by the investigators to render participation in the study inappropriate.\n6. those having contraindications to conduct an MRI study,\n7. those who are pregnant or lactating,\n8. patients who have refused to participate in this study.","ALL","50 Years",{"count":106,"type":107},60,"ESTIMATED","INTERVENTIONAL",[110],"NA","The objective of this study was to determine the effects of protocols of repetitive transcranial magnetic stimulation (rTMS) therapy based on the functional reserve of each patient with Parkinson's disease, compared to conventional high-frequency rTMS therapy on bilateral primary motor cortex (M1). Investigators hypothesized that the functional reserve of each patient with Parkinson's disease will be different, and therefore an appropriate simulating target for rTMS therapy is needed. In addition, this approach could be more effective compared to conventional protocols applied to patient with Parkinson's disease regardless of their severity, predicted mechanism of motor function recovery, or functional reserves.",[113],"Parkinson's Disease and Parkinsonism",[115,116,117],"Parkinson's Disease","rTMS","Functional reserve","2026-04-23",{"date":120,"type":121},"2026-04-28","ACTUAL",{"date":123,"type":121},"2024-02-20",{"date":125,"type":107},"2026-09-30",{"name":5,"class":6},1]